Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 28, 2010

Repligen Strikes Five-Year Extension to Supply Protein A to GE Healthcare

  • Repligen entered into a five-year supply agreement with GE Healthcare for recombinant Protein A, a consumable used in the manufacture of mAbs. This agreement provides for Repligen to continue to be a strategic supplier to GE Healthcare through 2014.

    GE Healthcare sells chromatography products that incorporate Repligen's recombinant Protein A to the biopharmaceutical industry for the manufacture of mAbs.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »